Jaideep Dudani
Chief Executive Officer Ouro Medicines
Seminars
Thursday 26th March 2026
Unraveling the Role of the BCMA in B-Cell Depletion for Autoimmunity
2:30 pm
- Highlighting the ability of BCMA T-cell engagers to induce the broad depletion of peripheral and tissue B-cells
- Analyzing the utility of BCMA targeting as a modality to eliminate long-lived plasma cells which can survive CD20 and CD19 depletion
- Discuss the pros and cons of targeting BCMA vs other B-cell targets
